Viewing Study NCT03406260


Ignite Creation Date: 2025-12-25 @ 2:15 AM
Ignite Modification Date: 2025-12-26 @ 12:44 AM
Study NCT ID: NCT03406260
Status: COMPLETED
Last Update Posted: 2019-12-02
First Post: 2018-01-16
Is NOT Gene Therapy: False
Has Adverse Events: True

Brief Title: A Study of Lasmiditan in Healthy Elderly Participants
Sponsor: Eli Lilly and Company
Organization:

Study Overview

Official Title: A Study to Investigate the Cardiovascular Effects of Lasmiditan in Healthy Elderly Subjects
Status: COMPLETED
Status Verified Date: 2018-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purposes of this study are to evaluate the effect of lasmiditan on blood pressure, as well as to look at the amount of study drug that gets into the blood stream and how long it takes the body to get rid of it in healthy elderly participants. The tolerability of the study drug will also be evaluated. Information about any side effects that may occur will also be collected. This study will take about 11 days, not including screening. Screening is required within 28 days prior to the start of the study.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
H8H-MC-LAIG OTHER Eli Lilly and Company View